|

tolododekin alfa Clinical Trials

2 actively recruiting trials across 2 locations

Also known as: ANK-101

Pipeline

Phase 1: 2

Top Sponsors

  • Ankyra Therapeutics, Inc2

Indications

  • Lung Cancer2
  • Non Small Cell Lung Cancer2
  • Cancer2
  • Metastasis to Soft Tissue1
  • Subcutaneous Tumor1

Indianapolis, Indiana1 trial

A Study of Tolododekin Alfa (ANK-101) in Combination With an Anti-PD-1/PD-L1 Antibody in Participants With Advanced Non-Small Cell Lung Cancer

Community Health Network

Phase 1

Bethesda, Maryland1 trial

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

National Cancer Institute

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.